In 2014, the UK National Screening Committee recommended against population screening for asymptomatic atrial fibrillation (AF) in those over the age of 65 years.¹ The committee’s decision was informed by concerns over suboptimal treatment pathways for AF, the need for more evidence over whether AF detected at screening carries the same long-term risk of stroke as AF found in the context of other conditions, and uncertainty over the cost-effectiveness of screening. A Cochrane review, published in 2016, concluded that there was moderate-quality evidence from one study that systematic and opportunistic screening of people aged 65 years and over increased the rate of detection of new cases of AF compared with normal practice.² It is …